The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2022 | BELLWAVE-001: nemtabrutinib in patients with R/R CLL/SLL
Jennifer Woyach, MD, Ohio State University College of Medicine, Columbus, OH, shares the results of a Phase I study of nemtabrutinib, a non-covalent BTK inhibitor in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL; NCT03162536). Whilst the initial results appear promising, with high response rates, a longer follow-up is required to evaluate the durability of response to this drug. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
